pbf-1129
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2018 (NCT03274479)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Adenosine A2b receptorANTAGONIST
ADORA2B antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05234307 | Phase 1 | Nov 1, 2022 | National Cancer Institute (NCI), Ohio State University |
| NCT03274479 | Phase 1 | Oct 1, 2018 | Ohio State University, Paloma Pharmaceuticals, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ohio State University | Academic/Hospital | 2 | 1 | 1 | 2018 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2022 |
| Paloma Pharmaceuticals, Inc. | For profit | 1 | 1 | 1 | 2018 |
3 organizations
Page 1 / 1